Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 2, 1998, Pages 122-130

  Burns, Karen L ^a,b   Ueki, Keisuke ^a   Jhung, Sarah L ^a   Koh, Jim ^a   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cdk4; CDKN2A; Glioblastoma; Immunohistochemistry; p16; pRb; RB

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; PROTEIN P16; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0031906358     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199802000-00003     Document Type: Article

References (40)

1. Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60
2. Jen J, Harper W, Bigner SH, et al. Deletion of p16 and pl5 genes in brain tumors. Cancer Res 1994;54:6353-58
3. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-24
4. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-36
5. Ueki K, Ono Y, Henson JW, von Deimling A, Louis DN. CDKN2/ p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53
6. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72
7. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-64
8. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 1995;55:20-23
9. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997;75:2-8
10. Moulton T, Samara G, Chung W, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995;146:613-19
11. Ueki K, Rubio M-P, Ramesh V, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Molec Genet 1994;3:1841-45
12. Merlo A, Herman JG, Mao L, et al. 5'CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1. Nature Med 1995;1:686-92
13. Fueyo J, Gomez-Manzano C, Bruner JM, et al. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 1996;13:1615-19
14. Costello JF, Berger MS, Su Huang H-J, Cavanee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10
15. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-21
16. Reifenberger G, Reifenberger J, Ichimura K, Melzter PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-4303
17. He J, Alien JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7
18. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP. Refined mapping of 12q13-q15 amplicons in malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996;56:5141-45
19. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A. Amplification of the cyclin dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol 1996;92:70-74
20. INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-45
21. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21
22. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-68
23. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Press; 1989
24. Louis DN, von Deimling A, Seizinger BR. A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 1992;141:777-82
25. Louis DN, Rubio M-P, Correa K, Gusella JF, von Deimling A. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropath Exp Neurol 1993;52:507-15
26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Nat Acad Sci USA 1996;93:9821-26
27. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994;54:6338-39
28. Sonoda Y, Yoshimoto T, Sekiya T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995;11:2145-49
29. Kyritsis AP, Zhang B, Zhang W, et al. Mutations of the p16 gene in gliomas. Oncogene 1996;12:63-67
30. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9
31. INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-11
32. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-78
33. INK4. Cancer Res 1994;54:5816-20
34. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene Product pRb. Cancer Res 1994;54: 6078-82
35. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995;55:2988-94
36. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995;55:493-97
37. INK4/MTSI tumor suppressor gene product. EMBO J 1995;14:503-11
38. Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995;61:115-20
39. INK4A genes in astrocytomas. Diagn Mol Pathol 1997;6:115-22
40. Nakamura M, Konishi N, Hiasa Y, et al. Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 1996;8:889-93